학술논문

Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar.
Document Type
Journal Article
Source
Journal of the American College of Cardiology (JACC). Feb2021, Vol. 77 Issue 5, p620-628. 9p.
Subject
*BIOLOGICAL products
*ANTILIPEMIC agents
*HYPERCHOLESTEREMIA
*LDL cholesterol
*RED yeast rice
*DIETARY supplements
*CHOLESTEROL
Language
ISSN
0735-1097
Abstract
The extracts of red yeast rice (RYR) are currently the most effective cholesterol-lowering nutraceuticals. This activity is mainly due to monacolin K, a weak reversible inhibitor of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, whose daily consumption causes a reduction in low-density lipoprotein (LDL)-cholesterol plasma levels up to 15% to 25% within 6 to 8 weeks. The decrease in LDL-cholesterol is accompanied by a proportional decrease in total and non-high-density lipoprotein cholesterol, plasma apolipoprotein B, and high-sensitivity C-reactive protein. Some trials suggest that RYR use is associated with improvement in endothelial function and arterial stiffness, whereas a long-term study supports its role in the prevention of cardiovascular events. Despite the statin-like mechanism of action, the risk related to 3 to 10 mg monacolin K taken per day is minimal (mild myalgia in previously severely statin-intolerant subjects). RYR could represent a therapeutic tool to support lifestyle improvement in managing mild to moderate hypercholesterolemia in low-risk patients, including those who cannot be treated with statins or other LDL-cholesterol-lowering therapies. [ABSTRACT FROM AUTHOR]